OPDUALAG 12 mg/mL
nivolumab and relatlimab-rmbw · INJECTION · E.R. Squibb & Sons, L.L.C.
Opdualag is a prescription injection containing two immunotherapy medicines that work together to help the immune system fight melanoma. It is administered intravenously and belongs to a class of drugs that block proteins that cancer cells use to hide from the immune system.
Key Facts
- Brand Name
- OPDUALAG
- Generic Name
- nivolumab and relatlimab-rmbw
- NDC Code (Product)
0003-7125- Manufacturer
- E.R. Squibb & Sons, L.L.C.
- Strength
- 12 mg/mL
- Dosage Form
- INJECTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761234
- Drug Class
- Programmed Death Receptor-1 Blocking Antibody [EPC]; Lymphocyte Activation Gene-3 Blocker [EPC]
- Marketing Start
- 03/18/2022
Recall History
No Recall HistoryFrequently Asked Questions
What is OPDUALAG used for?
Opdualag is a prescription injection containing two immunotherapy medicines that work together to help the immune system fight melanoma. It is administered intravenously and belongs to a class of drugs that block proteins that cancer cells use to hide from the immune system.
Is OPDUALAG a controlled substance?
OPDUALAG is not classified as a controlled substance by the DEA.
What is the generic name for OPDUALAG?
The generic name for OPDUALAG is nivolumab and relatlimab-rmbw. There are no other listed brand versions of nivolumab and relatlimab-rmbw.
What is the NDC code for OPDUALAG 12 mg/mL?
The NDC (National Drug Code) for OPDUALAG 12 mg/mL is 0003-7125, listed by E.R. Squibb & Sons, L.L.C..
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)